Back to News
Market Impact: 0.35
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookProduct LaunchesCompany Fundamentals
Alnylam Pharmaceuticals highlighted continued momentum for AMVUTTRA in transthyretin-mediated cardiomyopathy and identified upcoming clinical pipeline catalysts. The company also revised its 2026 TTR franchise revenue outlook in response to market changes, creating uncertainty around the longer-term commercial trajectory despite ongoing treatment uptake.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.05
Ticker Sentiment
ALNY0.30
More News
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
- China slows humanoid robot IPO rush as hype outruns reality
- Porsche could face another 4,000 job cuts, Handelsblatt reports
- Why is Telix Pharmaceuticals stock sliding today?
- Anthropic Mulls New AI Model Amid Investors' Pre-IPO Worries
- SoftBank plans more than $11 bln bond sale to fund OpenAI bets, Bloomberg reports